WO2010057962A3 - Crf conjugates with extended half-lives for use in inhibiting tumor progression - Google Patents

Crf conjugates with extended half-lives for use in inhibiting tumor progression Download PDF

Info

Publication number
WO2010057962A3
WO2010057962A3 PCT/EP2009/065513 EP2009065513W WO2010057962A3 WO 2010057962 A3 WO2010057962 A3 WO 2010057962A3 EP 2009065513 W EP2009065513 W EP 2009065513W WO 2010057962 A3 WO2010057962 A3 WO 2010057962A3
Authority
WO
WIPO (PCT)
Prior art keywords
crf
lives
tumor progression
inhibiting tumor
extended half
Prior art date
Application number
PCT/EP2009/065513
Other languages
French (fr)
Other versions
WO2010057962A2 (en
Inventor
William Henry
Original Assignee
Neutron Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutron Limited filed Critical Neutron Limited
Publication of WO2010057962A2 publication Critical patent/WO2010057962A2/en
Publication of WO2010057962A3 publication Critical patent/WO2010057962A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention relates to conjugates of CRF that have been modified to include a moiety that protects CRF from degradation and prolongs the half-life of CRF. The CRF conjugates of the invention have an increased half-life which results in a dose-sparing effect and less frequent administration.
PCT/EP2009/065513 2008-11-19 2009-11-19 Crf conjugates with extended half-lives WO2010057962A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11626008P 2008-11-19 2008-11-19
US61/116,260 2008-11-19

Publications (2)

Publication Number Publication Date
WO2010057962A2 WO2010057962A2 (en) 2010-05-27
WO2010057962A3 true WO2010057962A3 (en) 2010-07-22

Family

ID=42113509

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/065513 WO2010057962A2 (en) 2008-11-19 2009-11-19 Crf conjugates with extended half-lives

Country Status (1)

Country Link
WO (1) WO2010057962A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2349323A2 (en) * 2009-06-24 2011-08-03 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the treatment of cancer
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
WO2009027844A2 (en) * 2007-05-25 2009-03-05 Celtic Pharma Management L.P. Crf conjugates with extended half-lives
WO2009134396A2 (en) * 2008-04-30 2009-11-05 Neutron Row Methods of using corticotropin-releasing factor for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
WO2009027844A2 (en) * 2007-05-25 2009-03-05 Celtic Pharma Management L.P. Crf conjugates with extended half-lives
WO2009134396A2 (en) * 2008-04-30 2009-11-05 Neutron Row Methods of using corticotropin-releasing factor for the treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CARLSON KURT W ET AL: "Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs", March 2001, ANTICANCER RESEARCH, VOL. 21, NR. 2A, PAGE(S) 1173-1180, ISSN: 0250-7005, XP008122334 *
GRAZIANI ET AL: "Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype", MOLECULAR AND CELLULAR ENDOCRINOLOGY, ELSEVIER IRELAND LTD, IE LNKD- DOI:10.1016/J.MCE.2006.10.006, vol. 264, no. 1-2, 17 January 2007 (2007-01-17), pages 44 - 49, XP005736490, ISSN: 0303-7207 *
GRAZIANI GRAZIA ET AL: "CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway", ENDOCRINOLOGY, vol. 143, no. 3, March 2002 (2002-03-01), pages 807 - 813, XP002581842, ISSN: 0013-7227 *
WANG ET AL: "Corticotropin-releasing factor family and its receptors: Tumor therapeutic targets?", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US LNKD- DOI:10.1016/J.BBRC.2007.08.014, vol. 362, no. 4, 15 September 2007 (2007-09-15), pages 785 - 788, XP022249508, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2010057962A2 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
WO2009130602A3 (en) Factor ix conjugates with extended half-lives
EP2124728A4 (en) Enhanced laser vein contrast enhancer
MX344010B (en) Amatoxin-conjugates with improved linkers.
EP2303337A4 (en) Small molecule ligand-drug conjugates for targeted cancer therapy
IL205307A0 (en) Targeting micrornas for the treatment of liver cancer
MX344009B (en) Amatoxin-conjugates with improved linkages.
IL195876A0 (en) Pyrazine derivatives with extended conjugation and uses thereof
IL229996A0 (en) Biodegradable polymer-bioactive moiety conjugates
MX2011012599A (en) Immunomodulatory agent-polymeric compounds.
ZA200903173B (en) Cancer susceptibility variants on chr8q24.21
ZA201002428B (en) Combination therapy with antibody-drug conjugates
WO2009006577A3 (en) Compositions and methods for inhibiting ezh2
IL191850A0 (en) Targeting vector-phospholipid conjugates
WO2011020056A3 (en) Methods of treating cancer using galanin retargeted endpeptidases
WO2009027844A3 (en) Crf conjugates with extended half-lives
EP2038301A4 (en) Compositions and methods for targeting cancer-specific transcription complexes
WO2010014258A3 (en) Conjugates having a releasable linkage
WO2011054837A3 (en) Bifunctional prodrugs and drugs
WO2015040243A3 (en) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
WO2010057962A3 (en) Crf conjugates with extended half-lives for use in inhibiting tumor progression
WO2009108755A3 (en) Pharmaceutical combinations for the treatment of cancer
UA101831C2 (en) Combined use of cholestanol derivative for antitumor therapy
WO2010036977A3 (en) Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
SG10201700334XA (en) Composition useful for the prevention or reduction of the progression of prostate cancer
UA99332C2 (en) Herbicidal combinations having diflufenican and pinoxaden and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09804013

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09804013

Country of ref document: EP

Kind code of ref document: A2